Edition:
United Kingdom

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

20.50USD
5:59pm GMT
Change (% chg)

$0.25 (+1.23%)
Prev Close
$20.25
Open
$20.45
Day's High
$21.05
Day's Low
$20.30
Volume
121,400
Avg. Vol
230,936
52-wk High
$33.00
52-wk Low
$13.65

Select another date:

Mon, Nov 20 2017

UPDATE 3-Acorda Therapeutics scraps Parkinson's drug after deaths

* Last week company reported five deaths in tozadenant studies

Acorda Therapeutics scraps Parkinson's drug after deaths

Acorda Therapeutics Inc said on Monday it would stop developing its Parkinson's disease drug, tozadenant, less than a week after the company reported deaths in key studies testing the treatment.

Acorda Therapeutics scraps development of Parkinson's disease drug

Nov 20 Acorda Therapeutics Inc said on Monday it would terminate developing its drug to treat Parkinson's disease, a week after the drugmaker reported five deaths in key studies testing the treatment.

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Acorda reports five deaths in Parkinson's trial, shares plunge

Acorda Therapeutics Inc said five people died in trials for its Parkinson's disease drug, the latest in a series of setbacks for the drugmaker, sending its shares down 38 percent.

UPDATE 4-Acorda reports five deaths in Parkinson's trial, shares plunge

* Shares tank nearly 40 pct (Recasts, adds CEO and analyst comments, updates shares)

BRIEF-Acorda provides update on tozadenant development program

* Identified cases of agranulocytosis, possibly drug-related, in some cases associated with sepsis and death​

Acorda halts enrollment in Parkinson's disease trial

Nov 15 Acorda Therapeutics Inc said on Wednesday it has halted enroling patients in a late-stage trial testing its drug to treat Parkinson's disease, after reports of cases related to neutropenia, sepsis and death.

BRIEF-Acorda Therapeutics reports Q3 non-gaap earnings per share $0.43

* Q3 revenue $141.1 million versus I/B/E/S view $150.6 million

BRIEF-Acorda Q3 GAAP loss per share $0.55

* Acorda provides financial and pipeline update for third quarter 2017

Select another date: